North America Alpha-Glucosidase Inhibitors Market Size (2024 - 2029)

North America Alpha-Glucosidase Inhibitors Market Analysis

The North America Alpha-Glucosidase Inhibitors Market size is estimated at USD 0.28 billion in 2024, and is expected to reach USD 0.32 billion by 2029, growing at a CAGR of 2.5% during the forecast period (2024-2029).

In North America, the United States has the highest number of COVID cases with 82 million by April 2022, the country also registered the highest death rate. According to the Diabetes Voice article published in May 2020, close to 40,000 deaths are people with diabetes. In the North American region diabetes patients are more concerned about stocking up the monitoring and managing devices due to this the market increased during these years.

The North American region has witnessed an astounding increase in the prevalence of diabetes, in recent years. In developed countries, such as the United States and Canada, the rate of diabetes is at an all-time high, mainly due to lifestyle changes. Diabetes is associated with many health complications. According to FDA, comparing the population with and without diabetes, those with diabetes have a 300% increased risk of being hospitalized and thus incur more healthcare expenses compared to non-diabetic people. Patients with Type 2 diabetes require many corrections throughout the day for maintaining nominal blood glucose levels, such as the administration of additional insulin or ingestion of additional carbohydrates.

The World Health Assembly agreed on a Resolution to strengthen diabetes prevention and control in May 2021. It recommends actions such as increasing access to diabetes medicines and health products and assessing the feasibility and potential value of establishing a web-based tool to share information relevant to market transparency for diabetes medicines and health products.

The FDA approves AGIs for the treatment of type 2 diabetes mellitus. They have shown some benefits in type 1 diabetes mellitus and gestational diabetes mellitus but are not FDA-approved for these indications. Acarbose has been shown to decrease body weight in a worldwide observational study. AGIs are particularly useful for reducing postprandial hyperglycemia. They modestly decrease glycosylated hemoglobin levels and also reduce postprandial insulin concentration. Compared with oral antihyperglycemic drugs, they also reduce glucose variability throughout the day. They, however, do not affect fasting insulin and serum triglyceride concentrations.

This is driving the demand for Alpha-Glucosidase Inhibitors in North America, thereby driving the market in focus during the forecast period.

North America Alpha-Glucosidase Inhibitors Industry Segmentation

Type-2 diabetes is treated with medications called alpha-glucosidase inhibitors. This family of pharmaceuticals consists of two drugs: acarbose (Precose) and miglitol (Glyset). The North America alpha-glucosidase inhibitors market is segmented by geography (United States, Canada, and the Rest of North America). The report offers the value (in USD) and volume (in units) for the above segments. This report will provide a segment-wise breakdown (value and volume) for all the countries covered under the table of contents.